ABUS News and Press, Arbutus Biopharma Corporation From 08/13/22

On May 18, I wrote the first of three articles stating that healthcare stocks, and specifically biopharmaceuticals, had likely bottomed. XBI was at 68 and IBB 114. Both XBI and IBB have increased since then. I viewed the valuations a few months ago as being compelling in several insta...

Image source: The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q2 2022 Earnings Call Aug 04, 2022 , 8:45 a.m. ET Operator Continue reading For further details see: Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript

Arbutus Biopharma Corporation (ABUS) Q2 2022 Earnings Conference Call August 04, 2022 08:45 AM ET Company Participants Lisa Caperelli - Vice President of Investor Relations Bill Collier - President & Chief Executive Officer David Hastings - Chief Financial Of...

Arbutus Biopharma press release ( NASDAQ: ABUS ): Q2 GAAP EPS of -$0.10 beats by $0.03 . Revenue of $14.24M (+511.2% Y/Y) beats by $7.47M . For further details see: Arbutus Biopharma GAAP EPS of -$0.10 beats by $0.03, revenue of $14.24M beats by $7.47M

Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 04, 2...

Arbutus Biopharma ( NASDAQ: ABUS ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.12 (+47.8% Y/Y) and the consensus Revenue Estimate is $6.77M (+190.6% Y/Y). Over the last 3 months, EPS estima...

WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled it...

Arbutus Biopharma ( NASDAQ: ABUS ) on Wednesday said its phase 2a hepatitis B virus infection trial with partner Assembly Biosciences ( ASMB ) evaluating a combination involving drug candidates by both companies would continue, despite ASMB's decision to stop deve...

Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences’ core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022 WARMINSTER, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasda...

Two triple-combination studies using AB-729 for treatment of patients with Hepatitis B are expected in the 2nd half of 2022. A PD-L1 drug is being advanced in the pipeline to eventually add to a triple combination regimen with AB-729; In addition, potential to advance very same drug f...